therapies targeting B-cell biology? Specifically, they explore the effects of anti-CD20 therapeutic antibodies and targeting of B-cell receptor signaling kinases in conjunction with ATO or compound 40 (see figure). Despite individual reports of clinical activity in cHL, most studies testing rituximab (anti-CD20), idelalisib (phosphatidylinositol 3-kinase P110β [PI3K-P110β] inhibitor), and ibrutinib (BTK inhibitor) have been rather disappointing, and none of these drugs as single agents are anticipated to play a major role in clinical management of cHL. Therefore, the preclinical rationale to search for a “sensitizer” to these agents appears attractive. The presented in vitro studies demonstrate significantly decreased viability and enhanced cytotoxicity in L1236 and L428 cells treated with anti-CD20 therapeutic antibodies (rituximab and tositumomab) when cells were preincubated with ATRA or ATO. This effect could be further enhanced by addition of compound 40. However, the therapeutic effects of antibodies in cell line monoculture systems are inherently difficult to interpret, and immunocompetent in vivo models of cHL are lacking to dissect the differential effects of antigen-dependent cellular cytotoxicity and complement-mediated cytolysis. To an even larger extent, synergistic effects, measured by decreased viability across a wide range of cHL-derived cell lines, were observed with combination therapy of ATO/compound 40 and ibrutinib or idelalisib. Moreover, the authors show that ATO and compound 40 significantly increased CD19/CD20 phosphorylation, indicative of restored B-cell receptor and PI3K pathway signaling. Despite these convincing in vitro results, further studies are needed, as it remains an open question how exactly ibrutinib or idelalisib exerts its therapeutic activity, considering that HRS cells likely do not have the capacity to express functional, high-affinity B-cell receptors and is unclear how HRS cells might regain pathway addiction through differentiation therapy in vivo.

Overall, the presented study provides convincing proof of concept that pharmacological restoration of the B-cell phenotype provides valuable insight into cHL pathogenesis. However, the clinical utility of the identified compounds and overall strategy might be less certain and will be, in part, tied to host toxicity profiles. The landscape of cHL clinical management is rapidly evolving with the introduction of brentuximab vedotin and checkpoint inhibitors as US Food and Drug Administration–approved drugs and with extensive testing in randomized clinical trials focusing on various time points of patient management. Anticipated treatment changes might limit the room for additional concepts to be tested. However, it is worth noting that limiting treatment-related toxicity is still an underserved clinical need in cHL, and approaches that enable more targeted, hopefully less toxic therapies should still be explored with priority.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES


DOI 10.1182/blood-2016-11-746701
© 2017 by The American Society of Hematology

Lymphoid Neoplasia

Comment on Muchtar et al, page 82

Flow in a fibril-forming disease

Stefan Schöniland and Ute Hegenerart UNIVERSITY HOSPITAL HEIDELBERG

In this issue of Blood, Muchtar and colleagues report on the prognostic value of multiparametric flow cytometry (MFC) to measure clonal plasma cell burden at diagnosis and at end of treatment in patients with amyloid light-chain (AL) amyloidosis.1

Evaluation of a newly diagnosed patient with AL amyloidosis is a rather elaborate issue. The treating hematologist has to characterize and stage the underlying clonal bone marrow disorder, mostly a plasma cell dyscrasia. In addition, multiple organ systems have to be screened to judge how severely they are affected from the secreted toxic light chains and the deposited amyloid fibrils (see figure). The latter is most easily done with the validated staging systems using cardiac and renal biomarkers.2,3 The most commonly used hematologic prognostic factor is the free light-chain level (calculated as the difference between the involved and uninvolved light chain [dFLC]) with a cutoff of 180 mg/L at diagnosis.4 The primary goal of chemotherapy is achieving at least a very good partial response (VGPR) with a dFLC of <40 mg/L, which is associated with organ function and survival improvement.4 Using bone marrow aspirates and biopsies, the amyloidosis team of Mayo Clinic has previously reported a 10% cutoff for plasma cells percentage as another prognostic factor;5 however, it is difficult to reliably quantify cells on smears and slides. To more accurately measure clonal burden, they have now developed a MFC assay to quantify monocytic plasma cells at diagnosis and at the end of first-line treatment.

In a previous work, Paiva et al6 analyzed 35 patients with AL amyloidosis and found that a 1% cutoff of bone marrow plasma cells for MFC was of prognostic value for overall survival (OS) at 2 years (44% vs 90%). In the Mayo Clinic study, <2.5% of monocytic
plasma cells at diagnosis (analyzed in 173 patients) was significantly associated with an improved progression-free survival (PFS) and OS at 2 years of 56% and 70%, respectively. These results were also confirmed in a multivariate analysis, which included cardiac biomarkers. Importantly, in the current work, the 10% cutoff using the morphological assessment did not separate the groups.

In the second and more important part of the paper, the authors used MFC at the end of first-line treatment of minimal residual disease analysis in 82 patients. Patients achieving <0.1% of monotypic plasma cells had a better response (VGPR or better in 96% vs 36%) and consequently a longer PFS and OS at 2 years of 87% and 98%, respectively, than patients not achieving that level of reduction in plasma cells. However, probably due to the rather small sample size and short follow-up, there was only a trend toward improved PFS and no OS difference in patients with VGPR or better using the 0.1% MFC cutoff.

This study also found that prognostic (and especially plasma cell derived) parameters can depend on the administered therapy as MFC at diagnosis predicted for better outcome in the cohort of patients not receiving autologous stem cell transplantation (ASCT), but not in those treated with ASCT. This result underlines the need to evaluate prognostic factors in homogeneously treated cohorts and is reminiscent of previous studies from our group wherein the most prevalent cytogenetic aberration t(11;14) was a favorable prognostic factor in patients treated with ASCT but adverse in patients treated with bortezomib.

What should be the next steps? The new and interesting findings of the study of Muchtar et al have to be validated by other groups to confirm the prognostic value of MFC for OS. It would be optimal to validate the findings in prospective clinical trials using different treatment modalities. Most importantly, it must be determined if MFC after chemotherapy is prognostic in conjunction with serological response assessment and can predict the risk of early progression in patients with VGPR which could help the treating hematologist decide when to stop chemotherapy. Finally, within the amyloidosis community, a consensus (like in multiple myeloma) on how to use flow cytometry in AL amyloidosis (eg, amount of cells, which markers and gating strategies) should be determined.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES

DOI 10.1182/blood-2016-11-746693 © 2017 by The American Society of Hematology
Flow in a fibril-forming disease

Stefan Schönland and Ute Hegenbart